Noviosense

Executive Summary

Noviosense, based in Enschede, Netherlands, is a medical device company developing a non-invasive tear glucose sensor for continuous glucose monitoring in diabetic patients. The company has demonstrated clinically relevant accuracy correlating tear glucose levels with blood glucose, and is currently conducting a second 24-patient study in type 1 diabetics to validate its sensor. Founded in 2016, Noviosense aims to offer a painless alternative to traditional fingerstick and invasive continuous glucose monitors (CGMs). The tear glucose sensor is worn on the lower eyelid and measures glucose in tears, providing real-time data without the need for calibration or skin punctures. With the global CGM market expected to grow significantly, Noviosense's unique approach addresses a major unmet need for non-invasive monitoring. The company is at a critical Phase 2 stage, with the ongoing study being a key value inflection point. Successful validation could position Noviosense for partnerships, regulatory submissions, and commercialization. However, the technology still faces challenges in consistency and correlation across diverse patient populations. Overall, Noviosense represents a promising but early-stage opportunity in the non-invasive glucose monitoring space.

Upcoming Catalysts (preview)

• Q3 2026Completion of 24-patient study in type 1 diabetics75% success
• Q4 2026Publication or presentation of study results at a major diabetes conference60% success
• 2027Strategic partnership or licensing deal with a larger diabetes device company50% success